-
Letter to Register Shareholders - NEW ARRANGEMENTS ON DISSEMINATION OF CORPORATE COMMUNICATIONS2024-03-11
-
Letter to Non-Register Shareholders - NEW ARRANGEMENTS ON DISSEMINATION OF CORPORATE COMMUNICATIONS2024-03-11
-
NEW ARRANGEMENTS ON DISSEMINATION OF CORPORATE COMMUNICATIONS2024-03-11
-
CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG2025-01-10
-
VOLUNTARY ANNOUNCEMENT - B7-H3-TARGETED ANTIBODY-DRUG CONJUGATE HS-20093 RECEIVED FDA BREAKTHROUGH THERAPY DESIGNATION IN LATE-LINE RELAPSED OR REFRACTORY OSTEOSARCOMA2025-01-07
-
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 20242025-01-03
-
INSIDE INFORMATION - LICENSE AGREEMENT WITH MSD2024-12-18
-
VOLUNTARY ANNOUNCEMENT - THE CLINICAL TRIAL APPROVAL FOR HS-20110 FOR INJECTION ISSUED BY THE NATIONAL MEDICAL2024-12-17
-
VOLUNTARY ANNOUNCEMENT - B7-H3-TARGETED ANTIBODY-DRUG CONJUGATE HS-20093 RECEIVED EMA PRIORITY MEDICINES DESIGNATION2024-12-16
-
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 20242024-12-03
-
VOLUNTARY ANNOUNCEMENT - FOUR INNOVATIVE DRUGS RENEWED IN THE 2024 NATIONAL REIMBURSEMENT DRUG LIST2024-11-28
-
VOLUNTARY ANNOUNCEMENT - THE FIFTH NEW DRUG APPLICATION OF AMEILE (AUMOLERTINIB MESILATE TABLETS) WAS ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION2024-11-27
